Fc engineering enhances antibody half-life

A Nature Biotechnology article published online January 17 reveals that Xencor Inc.’s proprietary Fc engineering extends the half-life of antibodies while maintaining their potency and extending duration of action. These results, published in an article entitled, “Enhanced antibody half-life improves in vivo activity” demonstrate the potential of Fc engineering to impact the flexibility of route, schedule and dose for nearly any antibody.

“Enhanced antibody half-life improves in vivo activity”

“Competition is heating up in biologics, with patent expirations looming and the market demanding drugs that will improve patient compliance,” said John Desjarlais, Ph.D., vice president of research at Xencor and lead author on the study. “Although monoclonal antibodies have reasonably long half-lives, market pressures for less frequent dosing schedules can reduce efficacy. In this Nature Biotechnology paper, our research shows that it’s possible with pharmacokinetic engineering to maintain efficacy of antibody drugs, but with less frequent dosing and greater patient convenience.”

To determine whether improved affinity to the neonatal Fc receptor (FcRn) can result in enhanced therapeutic efficacy, Xencor researchers tested whether antibodies with half-lives extended up to five-fold in human FcRn transgenic mice and three-fold in cynomolgus monkeys retain efficacy at longer dosing intervals. Data for the Fc variant constructed in the context of VEGF antibody, bevacizumab (Avastin), which is approved for the treatment of colorectal, lung, breast and renal cancers, showed significantly improved efficacy compared to bevacizumab in tumor xenograft models. These results are consistent with the improved efficacy in tumor xenograft models seen with an anti-EGFR antibody variant of cetuximab (Erbitux) versus cetuximab, which is approved for the treatment of colorectal and head and neck cancers.

“While we continue to expand our Fc engineering capabilities and work with partners like Pfizer and Centocor to optimize their antibodies, Xencor is also moving its internal antibody pipeline forward including XmAb2513 in a Phase I trial for lymphoma and pre-clinical antibodies for B-cell malignancies and autoimmune diseases,” added Bassil Dahiyat, Ph.D., president and CEO of Xencor.


Xencor, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Comprehensive analysis outlines the potential toxicities of antibody drug conjugates